Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Organon (OGN)
NYSE:OGN
Organon (OGN) Stock Price & Analysis
770 Followers
OGN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$10.53 - $22.54
Previous Close$20.31
Volume913.77K
Average Volume (3M)1.91M
Market Cap
$5.22B
Enterprise Value$13.36B
Total Cash (Recent Filing)$575.00M
Total Debt (Recent Filing)$8.71B
Price to Earnings (P/E)5.0
Beta1.00
Next Earnings
Aug 07, 2024EPS Estimate
$1.17Last Dividend Ex-Date
May 10, 2024Dividend Yield5.41%
Share Statistics
EPS (TTM)4.08
Shares Outstanding257,170,727
10 Day Avg. Volume1,755,216
30 Day Avg. Volume1,906,466
Standard Deviation0.13
R-Squared0.12
Alpha-0.00368
Financial Highlights & Ratios
Price to Book (P/B)-1.02
Price to Sales (P/S)3.35
Price to Cash Flow (P/CF)17.60
P/FCF Ratio14.60
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.11
Enterprise Value/Gross Profit3.57
Enterprise Value/Ebitda15.20
Forecast
1Y Price Target
$23.00Price Target Upside14.31% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
Organon News
PremiumCompany Announcements
Organon Q1 2024 Financial Results Presentation Update
Bulls Say, Bears Say
Bulls Say
Earnings1Q results came out ahead of expectations on both the top and bottom lines.
Financial StrategyWith OGN on track to deliver ~$1bn in FCF, the capital allocation strategy remains prudently balanced.
Portfolio PerformanceHeadlining components of the portfolio performed well, including Nexplanon +35% in the US.
Bears Say
Financial PerformanceOverall, 1Q revenues are expected to be $1.55bn, approximately 2% lower than the prior estimate of $1.58bn, and EPS is projected at $1.04, down from $1.06 previously.
GuidanceThe decision to maintain all components of guidance was framed as conservatism, noting both the still early time point in the year as well as the potential for FX impacts to weigh.
Revenue EstimatesUpdates to the model ahead of 1Q24 earnings based on the review of IQVIA prescription trends and management commentary prompt a lowering of revenue estimates for both Nexplanon and Hadlima.
---
Ownership Overview
0.20% Insiders
34.63% Mutual Funds
24.97% Other Institutional Investors
40.20% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
OGN FAQ
What was Organon’s price range in the past 12 months?
Organon lowest stock price was $10.53 and its highest was $22.54 in the past 12 months.
What is Organon’s market cap?
Currently, no data Available
When is Organon’s upcoming earnings report date?
Organon’s upcoming earnings report date is Aug 07, 2024 which is in 35 days.
How were Organon’s earnings last quarter?
Organon released its earnings results on May 02, 2024. The company reported $1.22 earnings per share for the quarter, beating the consensus estimate of $0.978 by $0.242.
Is Organon overvalued?
According to Wall Street analysts Organon’s price is currently Undervalued.
Does Organon pay dividends?
Organon pays a Quarterly dividend of $0.28 which represents an annual dividend yield of 5.41%. See more information on Organon dividends here
What is Organon’s EPS estimate?
Organon’s EPS estimate is $1.17.
How many shares outstanding does Organon have?
Organon has 257,170,720 shares outstanding.
What happened to Organon’s price movement after its last earnings report?
Organon reported an EPS of $1.22 in its last earnings report, beating expectations of $0.978. Following the earnings report the stock price went up 3.554%.
Which hedge fund is a major shareholder of Organon?
Among the largest hedge funds holding Organon’s share is Slate Path Capital LP. It holds Organon’s shares valued at 97M.
---
Organon Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$23.00 (14.31% Upside)
$23.00 (14.31% Upside)
Blogger Sentiment
Bullish
OGN Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 4.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.1%
Last 30 Days ▲ 0.7%
Last 30 Days ▲ 0.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
4.27%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
10.48%
Trailing 12-Months
Company Description
Organon
Organon & Co is a science-based global pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. Its two operating segments are the Organon Products segment and the Merck Retained Products segment. It operates in the United States, China, Japan, Korea, and countries in Europe.
---
OGN Company Deck
---
OGN Earnings Call
Q1 2024
0:00 / 0:00
---
OGN Stock 12 Month Forecast
Average Price Target
$23.00
▲(14.31% Upside)
Technical Analysis
Best Analysts Covering OGN
1 Year
1 Year Success Rate
5/7 ratings generated profit
1 Year Average Return
+17.76%
assigned a buy rating 2 months ago
Copying David Amsellem's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +17.76% per trade.
---